Overview

Effects of Nystatin Suspension Oral Application on Oral Microbial Community

Status:
Recruiting
Trial end date:
2022-01-30
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to examine the effect of a prescription mouth rinse (Nystatin),an FDA approved drug, on the different types of bacteria in the mouth. Results from this study may help understand the effect that Nystatin oral rinse has on certain types of oral bacteria, which may also cause tooth decay.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Rochester
Treatments:
Nystatin
Criteria
Inclusion Criteria:

- Willing to participate in this study and able to come for follow-up appointments.

- Has positive oral Candida detection and the amount of oral Candida meet the laboratory
criteria for diagnosing oral Candidiasis (>= 400 colony forming unit in saliva).

- Has ≥ 10,000 CFU/mL of S. mutans in the saliva (justification: individuals with ≥
10,000 CFU/mL salivary S. mutans are considered at elevated risk for dental caries).

- Ability to consent, comply with all study procedures and be available for the duration
of the study.

Exclusion Criteria:

- visible signs of candidiasis on the mucosa or tongue at screening (Patients will be
referred for treatment immediately)

- Patient with systemic diseases, such as HIV, cancer or diabetes. This will be answered
by study participants and further confirmed by using electronic medical record (EPIC)
for those participants who have records in the EPIC system. (Justification: patient
with systemic diseases is that patients with these conditions are more prone to yeast
and bacterial infection)

- History of local (oral) or systemic antibiotics or antifungal medication within the
last 3 months. This will be answered by study participants and further confirmed by
using electronic medical record (EPIC) for those participants who have records in the
EPIC system.

- Women who are currently pregnant or reported that she is currently breast feeding . A
pregnancy test (urine test) will be conducted to exclude participants who are
pregnant. Rational of excluding pregnant women and women are currently breastfeeding
their children: Nystatin oral suspension is classified as FDA pregnancy risk category
C. It's also unknown whether nystatin is excreted in human milk.